Beijing Cancer Prevention and Control Society Esophageal Cancer Commission was established to lead China's esophageal cancer diagnosis and treatment into a new stage.

Today (September 6), in order to promote the national esophageal cancer in many fields of authoritative experts to explore and exchange, leading China's comprehensive diagnosis and treatment of esophageal cancer into a new stage, the Beijing Society for Cancer Prevention and Control today officially announced the establishment of the Beijing Society for The Prevention and Control of Cancer esophageal cancer professional committee, and in Beijing to "self-improvement, innovation, cooperation" as the theme of the establishment of the professional committee of esophageal cancer conference and comprehensive treatment of esophageal cancer seminar.
esophageal cancer is a high incidence and idesophageal tumor in China, with about 246,000 new cases per year, accounting for about half of the global number of cases and about 188,000 deaths, ranking fourth in the national mortality rate of malignant tumors. At the founding meeting of
, Professor Shen Lin, Chairman of the Rotating Committee of the Society, Chairman of the Professional Committee on Esophageal Cancer and Vice President of Peking University Cancer Hospital, delivered a speech introducing the current research progress of esophageal cancer and the objectives of the ad-committee: "In the past few decades, no breakthrough has been made in the treatment of esophageal cancer, and the survival status of patients has not improved significantly."
, with the exploration and application of innovative treatments represented by immunotherapy in recent years, we see that there is still great potential to improve the survival rate of esophageal cancer.
at the upcoming academic conference, we will share data on the historic breakthrough in the treatment of esophageal cancer, which will bring about a tremendous change in the treatment landscape of esophageal cancer.
hope that through the establishment of the adm committee, with the joint efforts of experts and clinicians of esophageal cancer in China, a new situation will be created in the field of esophageal cancer in China and contribute to the research of esophageal cancer in the world.
" it is known that in China, about 90% of esophageal cancer patients are squamous cancer, and about 70% of patients are diagnosed with the middle and late stage, the five-year survival rate is only 15% to 20%.
addition to the improvement of the level of diagnosis and treatment, Professor Shen Lin also expressed his expectation for the improvement of access to innovative drugs at the media communication meeting after the meeting.
said that through the joint efforts of all sectors of society, the esophageal cancer immunotherapy program with precise benefits and breakthrough efficacy should benefit more Chinese patients.
with the improvement of accessability, will help promote the overall survival rate of esophageal cancer in China into a new stage.
For the significance of the establishment of the admin committee, Comrade Zhang Wei, Executive Vice President of the Beijing Cancer Prevention and Control Society, said: "Cancer prevention and treatment is one of the special programs of 'Healthy China 2030', esophageal cancer as a high incidence, high death of 'Chinese characteristics' digestive tract tumor, promote its overall level of diagnosis and treatment, improve the overall survival rate, will make an important contribution to the realization of the goal of healthy China."
believe that the establishment of the Beijing Society for The Prevention and Control of Esophageal Cancer Professional Committee will become an important driving force for the improvement of the level of esophageal cancer prevention and treatment in China.
"The main members of the Esophageal Cancer Professional Committee of the Beijing Society for Cancer Prevention and Control include authoritative esophageal cancer experts from Beijing University Cancer Hospital, Oncology Hospital of the Chinese Academy of Medical Sciences, Hebei Medical University Fourth Hospital, Jiangsu Cancer Hospital, Harbin Medical University Affiliated Oncology Hospital, Zhengzhou University First Affiliated Hospital and Zhengzhou University Affiliated Oncology Hospital, and have absorbed clinical doctors from more than 70 hospitals in China, including internal medicine, surgery, radiotherapy, imaging, pathology and other disciplines.
In the future, the adm committee will further improve the standardized and standardized diagnosis and treatment level of esophageal cancer in China by conducting high-quality, multi-center clinical research, guiding the prevention, diagnosis and treatment strategies of esophageal cancer in China, and through a series of popular science education activities and academic exchanges.
name source: Medical Valley network !-- content display end -- !-- determine whether the login ends.